Last update: Sept. 2, 2017
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate is Lisdexamfetamine Mesilate in Chemical name.
Is written in other languages:(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate is also known as
(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate belongs to this group or family:
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A prodrug that is metabolized directly in the intestine to dextroamphetamine. It is used to treat Attention Deficit Hyperactivity Disorder (ADHD) and bulimia.
Dextroamfetamine is a sympathomimetic drug, central nervous system stimulant, whose action and uses are similar to amphetamine (see information) which is its dextro isomer.
It is excreted in breast milk, concentrating about 3 times more than in plasma and resulting in a relative dose of around 6% for the infant (Ilett, 2007).
In infants whose mothers were taking dexamfetamine as treatment for ADHD, levels ranging from undetectable to 14% of maternal plasma levels have been measured and no problems were observed in the clinical follow-up of these infants (Ilett, 2007).
There is little information on the impact of amphetamine abuse on infant development and health (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower rates of breastfeeding (Oei, 2010).
There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected (Öhman, 2015).
During breastfeeding, the therapeutic use (ADHD, bulimia) of amphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss.
Its use as an illegal drug is totally discouraged (Oei, 2012).
See below the information of this related product: